To screen ETFs by asset class, performance, yield and more, check out the
up today on orphan drug approval by FDA. Fading in premarket. Some may be pushing it down to buy in regular market. Worth watching.
Add a reply...
Latest StockTalks »
people get DYAX breaking news and analysis by email alert.
Get email alerts on DYAX »
Get latest price
From other sites
Dyax (DYAX) Shows Strength: Stock Adds 6.6% in Session - Tale of the Tape
at Zacks.com (Aug 10, 2015)
Dyax Enters Oversold Territory (DYAX)
at Nasdaq.com (Aug 6, 2015)
Dyax : Gets FDA Breakthrough Therapy Designation for DX-2930
at 4-traders.com (Jul 17, 2015)
Commit To Purchase Dyax Corp At $22.50, Earn 14.5% Annualized Using Options
at Nasdaq.com (Jul 10, 2015)
Dyax Hereditary Angioedema Drug Gets Breakthrough Status - Analyst Blog
at Zacks.com (Jul 8, 2015)
Xignite quote data
© 2015 Seeking Alpha